Nasen Odt (Zolpidem Tartrate)

Zolpidem tartrate binds to the benzodiazepine site on GABA‑A receptors, acting as a positive allosteric modulator. This enhances GABA‑mediated inhibition in the brain, leading to decreased neuronal activity and facilitating the onset of sleep.

The appropriate dose of Nasen Odt is determined by the prescribing clinician based on the patient’s medical condition, age, and response to therapy. Dosage instructions are provided on the prescription label.

The safety of zolpidem tartrate in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To request Nasen Odt, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with benzodiazepine hypnotics, zolpidem tartrate has a shorter half‑life and a more selective binding profile, which generally results in fewer next‑day residual effects. It is often preferred for patients needing rapid sleep onset without prolonged sedation.

Nasen Odt should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture and direct sunlight to maintain stability and potency.

Nasen Odt is an orally disintegrating tablet that dissolves on the tongue without water. It should be taken shortly before bedtime, after ensuring the patient has a full night’s sleep opportunity, and only when the patient can obtain a full night of sleep.

Serious risks include complex sleep behaviors such as sleepwalking or driving while not fully awake, allergic reactions, and rare psychiatric effects like hallucinations or depression. Patients should be monitored for any unusual behaviors or mood changes.

Nasen Odt is contraindicated in patients with known hypersensitivity to zolpidem or any component of the tablet, in those with severe hepatic impairment, and in individuals who are pregnant or breastfeeding unless the benefits outweigh the risks.